Related Experiment Video
Updated: Mar 25, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.5K
Assessing Circulating Factor VIIa-Antithrombin Complexes in Acute Ischemic Stroke: A Pilot Study
Artur Słomka1, Milena Świtońska2, Władysław Sinkiewicz3
11 Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Summary
Patients with ischemic stroke have lower levels of Factor VII (FVII), Factor VIIa-antithrombin complexes (FVIIa-AT), and total tissue factor (TF), but higher levels of tissue factor-bearing microparticles (MPs-TF). Alteplase treatment showed a minor effect on FVII levels.
Area of Science:
- Biochemistry
- Hematology
- Neurology
Background:
- Acute ischemic stroke is a complex condition involving hemostatic system alterations.
- Understanding the role of specific coagulation factors and microparticles is crucial for stroke management.
Purpose of the Study:
- To quantify levels of Factor VII (FVII), FVIIa-antithrombin complexes (FVIIa-AT), total tissue factor (TF), and TF-bearing microparticles (MPs-TF) in acute ischemic stroke patients.
- To investigate associations between these hemostatic markers, blood sampling time, treatment, and patient outcomes.
Main Methods:
- Plasma levels of FVII, FVIIa-AT, TF, and MPs-TF were measured using ELISA in 33 ischemic stroke patients and 20 controls.
- Patients were categorized into thrombolysis (n=13) and non-thrombolysis (n=20) groups.
- Clinical assessments included NIH Stroke Scale and Barthel Index on days 1 and 7 post-stroke.
Main Results:
- Ischemic stroke patients exhibited significantly lower plasma FVII, FVIIa-AT, and total TF compared to controls.
- Conversely, MPs-TF levels were significantly elevated in stroke patients versus controls.
- The thrombolysis group showed a significant decrease in FVII levels from day 1 to day 7 post-stroke.
Conclusions:
- Factor VII, FVIIa-AT, and total TF are downregulated, while MPs-TF are upregulated in acute ischemic stroke.
- Alteplase treatment demonstrated a subtle but significant impact on plasma FVII levels.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:16Clot Retraction and Fibrinolysis
10.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.2K
01:30Venous Thrombosis I: Introduction
668
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
668